Unlocking ferroptosis in prostate cancer - the road to novel therapies and imaging markers.
Journal
Nature reviews. Urology
ISSN: 1759-4820
Titre abrégé: Nat Rev Urol
Pays: England
ID NLM: 101500082
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
accepted:
04
03
2024
medline:
17
4
2024
pubmed:
17
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Ferroptosis is a distinct form of regulated cell death that is predominantly driven by the build-up of intracellular iron and lipid peroxides. Ferroptosis suppression is widely accepted to contribute to the pathogenesis of several tumours including prostate cancer. Results from some studies reported that prostate cancer cells can be highly susceptible to ferroptosis inducers, providing potential for an interesting new avenue of therapeutic intervention for advanced prostate cancer. In this Perspective, we describe novel molecular underpinnings and metabolic drivers of ferroptosis, analyse the functions and mechanisms of ferroptosis in tumours, and highlight prostate cancer-specific susceptibilities to ferroptosis by connecting ferroptosis pathways to the distinctive metabolic reprogramming of prostate cancer cells. Leveraging these novel mechanistic insights could provide innovative therapeutic opportunities in which ferroptosis induction augments the efficacy of currently available prostate cancer treatment regimens, pending the elimination of major bottlenecks for the clinical translation of these treatment combinations, such as the development of clinical-grade inhibitors of the anti-ferroptotic enzymes as well as non-invasive biomarkers of ferroptosis. These biomarkers could be exploited for diagnostic imaging and treatment decision-making.
Identifiants
pubmed: 38627553
doi: 10.1038/s41585-024-00869-9
pii: 10.1038/s41585-024-00869-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Springer Nature Limited.
Références
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
pubmed: 36633525
doi: 10.3322/caac.21763
Moreira, D. M. et al. Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin. Genitourin. Cancer 15, 60–66. e62 (2017).
pubmed: 27692812
doi: 10.1016/j.clgc.2016.08.018
Chen, X., Comish, P. B., Tang, D. & Kang, R. Characteristics and biomarkers of ferroptosis. Front. Cell Dev. Biol. 9, 637162 (2021).
pubmed: 33553189
pmcid: 7859349
doi: 10.3389/fcell.2021.637162
Yang, W. S. et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis. Proc. Natl Acad. Sci. USA 113, E4966–E4975 (2016).
pubmed: 27506793
pmcid: 5003261
doi: 10.1073/pnas.1603244113
Lin, Z. et al. The lipid flippase SLC47A1 blocks metabolic vulnerability to ferroptosis. Nat. Commun. 13, 7965 (2022).
pubmed: 36575162
pmcid: 9794750
doi: 10.1038/s41467-022-35707-2
Catala, A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 157, 1–11 (2009).
pubmed: 18977338
doi: 10.1016/j.chemphyslip.2008.09.004
Gao, M. et al. Role of mitochondria in ferroptosis. Mol. Cell 73, 354–363 e353 (2019).
pubmed: 30581146
doi: 10.1016/j.molcel.2018.10.042
Park, M. W. et al. NOX4 promotes ferroptosis of astrocytes by oxidative stress-induced lipid peroxidation via the impairment of mitochondrial metabolism in Alzheimer’s diseases. Redox Biol. 41, 101947 (2021).
pubmed: 33774476
pmcid: 8027773
doi: 10.1016/j.redox.2021.101947
Yan, B. et al. Membrane damage during ferroptosis is caused by oxidation of phospholipids catalyzed by the oxidoreductases POR and CYB5R1. Mol. Cell 81, 355–369 e310 (2021).
pubmed: 33321093
doi: 10.1016/j.molcel.2020.11.024
Zhang, S. et al. Double-edge sword roles of iron in driving energy production versus instigating ferroptosis. Cell Death Dis. 13, 40 (2022).
pubmed: 35013137
pmcid: 8748693
doi: 10.1038/s41419-021-04490-1
von Krusenstiern, A. N. et al. Identification of essential sites of lipid peroxidation in ferroptosis. Nat. Chem. Biol. 19, 719–730 (2023).
doi: 10.1038/s41589-022-01249-3
Yang, W. S. & Stockwell, B. R. Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165–176 (2016).
pubmed: 26653790
doi: 10.1016/j.tcb.2015.10.014
Conrad, M. & Friedmann Angeli, J. P. Glutathione peroxidase 4 (Gpx4) and ferroptosis: what’s so special about it? Mol. Cell Oncol. 2, e995047 (2015).
pubmed: 27308484
pmcid: 4905320
doi: 10.4161/23723556.2014.995047
Lu, S. C. Glutathione synthesis. Biochim. Biophys. Acta 1830, 3143–3153 (2013).
pubmed: 22995213
doi: 10.1016/j.bbagen.2012.09.008
Du, Y. & Guo, Z. Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discov. 8, 501 (2022).
pubmed: 36581640
pmcid: 9800531
doi: 10.1038/s41420-022-01297-7
Li, Q. et al. Understanding sorafenib-induced ferroptosis and resistance mechanisms: implications for cancer therapy. Eur. J. Pharmacol. 955, 175913 (2023).
pubmed: 37460053
doi: 10.1016/j.ejphar.2023.175913
Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180–1191 (2014).
pubmed: 25402683
doi: 10.1038/ncb3064
Yan, H. F. et al. Ferroptosis: mechanisms and links with diseases. Signal. Transduct. Target. Ther. 6, 49 (2021).
pubmed: 33536413
pmcid: 7858612
doi: 10.1038/s41392-020-00428-9
Mao, C. et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586–590 (2021).
pubmed: 33981038
pmcid: 8895686
doi: 10.1038/s41586-021-03539-7
Cirilli, I. et al. Role of coenzyme Q
pubmed: 34439573
pmcid: 8389239
doi: 10.3390/antiox10081325
Bentinger, M., Tekle, M. & Dallner, G. Coenzyme Q — biosynthesis and functions. Biochem. Biophys. Res. Commun. 396, 74–79 (2010).
pubmed: 20494114
doi: 10.1016/j.bbrc.2010.02.147
Kraft, V. A. N. et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent. Sci. 6, 41–53 (2020).
pubmed: 31989025
doi: 10.1021/acscentsci.9b01063
Lei, G., Zhuang, L. & Gan, B. Targeting ferroptosis as a vulnerability in cancer. Nat. Rev. Cancer 22, 381–396 (2022).
pubmed: 35338310
pmcid: 10243716
doi: 10.1038/s41568-022-00459-0
Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).
pubmed: 24844246
pmcid: 4054777
doi: 10.7554/eLife.02523
Jeong, S. D. et al. Enhanced immunogenic cell death by apoptosis/ferroptosis hybrid pathway potentiates PD-L1 blockade cancer immunotherapy. ACS Biomater. Sci. Eng. 8, 5188–5198 (2022).
pubmed: 36449494
doi: 10.1021/acsbiomaterials.2c00950
Lei, G. et al. The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. Cell Res. 30, 146–162 (2020).
pubmed: 31949285
pmcid: 7015061
doi: 10.1038/s41422-019-0263-3
Viswanathan, V. S. et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature 547, 453–457 (2017).
pubmed: 28678785
pmcid: 5667900
doi: 10.1038/nature23007
Tousignant, K. D. et al. Therapy-induced lipid uptake and remodeling underpin ferroptosis hypersensitivity in prostate cancer. Cancer Metab. 8, 11 (2020).
pubmed: 32577235
pmcid: 7304214
doi: 10.1186/s40170-020-00217-6
Ghoochani, A. et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 81, 1583–1594 (2021).
pubmed: 33483372
pmcid: 7969452
doi: 10.1158/0008-5472.CAN-20-3477
Yang, Y. et al. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration-resistant prostate cancer. Oncol. Rep. 45, 25 (2021).
pubmed: 33649848
doi: 10.3892/or.2021.7976
Mathur, D. et al. PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition. Cancer Discov. 7, 380–390 (2017).
pubmed: 28255082
pmcid: 5562025
doi: 10.1158/2159-8290.CD-16-0612
Lv, Z. et al. Identifying a ferroptosis-related gene signature for predicting biochemical recurrence of prostate cancer. Front. Cell Dev. Biol. 9, 666025 (2021).
pubmed: 34778244
pmcid: 8586218
doi: 10.3389/fcell.2021.666025
Mao, C., Liu, X., Yan, Y., Olszewski, K. & Gan, B. Reply to: DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition. Nature 619, E19–E23 (2023).
pubmed: 37407682
doi: 10.1038/s41586-023-06270-7
Mishima, E. et al. DHODH inhibitors sensitize to ferroptosis by FSP1 inhibition. Nature 619, E9–E18 (2023).
pubmed: 37407687
doi: 10.1038/s41586-023-06269-0
Yoo, S. E. et al. Gpx4 ablation in adult mice results in a lethal phenotype accompanied by neuronal loss in brain. Free. Radic. Biol. Med. 52, 1820–1827 (2012).
pubmed: 22401858
pmcid: 3341497
doi: 10.1016/j.freeradbiomed.2012.02.043
Mei, J., Webb, S., Zhang, B. & Shu, H. B. The p53-inducible apoptotic protein AMID is not required for normal development and tumor suppression. Oncogene 25, 849–856 (2006).
pubmed: 16186796
doi: 10.1038/sj.onc.1209121
Doll, S. et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat. Chem. Biol. 13, 91–98 (2017).
pubmed: 27842070
doi: 10.1038/nchembio.2239
Rodriguez, R., Schreiber, S. L. & Conrad, M. Persister cancer cells: iron addiction and vulnerability to ferroptosis. Mol. Cell 82, 728–740 (2022).
pubmed: 34965379
doi: 10.1016/j.molcel.2021.12.001
Scheinberg, T., Mak, B., Butler, L., Selth, L. & Horvath, L. G. Targeting lipid metabolism in metastatic prostate cancer. Ther. Adv. Med. Oncol. 15, 17588359231152839 (2023).
pubmed: 36743527
pmcid: 9893394
doi: 10.1177/17588359231152839
Mah, C. Y., Nassar, Z. D., Swinnen, J. V. & Butler, L. M. Lipogenic effects of androgen signaling in normal and malignant prostate. Asian J. Urol. 7, 258–270 (2020).
pubmed: 32742926
doi: 10.1016/j.ajur.2019.12.003
Poulose, N. et al. Genetics of lipid metabolism in prostate cancer. Nat. Genet. 50, 169–171 (2018).
pubmed: 29335543
doi: 10.1038/s41588-017-0037-0
Scaglia, N., Frontini-Lopez, Y. R. & Zadra, G. Prostate cancer progression: as a matter of fats. Front. Oncol. 11, 719865 (2021).
pubmed: 34386430
pmcid: 8353450
doi: 10.3389/fonc.2021.719865
Castelli, S., De Falco, P., Ciccarone, F., Desideri, E. & Ciriolo, M. R. Lipid catabolism and ROS in cancer: a bidirectional liaison. Cancers 13, 5484 (2021).
pubmed: 34771647
pmcid: 8583096
doi: 10.3390/cancers13215484
Iglesias-Gato, D. et al. The proteome of primary prostate cancer. Eur. Urol. 69, 942–952 (2016).
pubmed: 26651926
doi: 10.1016/j.eururo.2015.10.053
Magtanong, L. et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem. Biol. 26, 420–432 e429 (2019).
pubmed: 30686757
pmcid: 6430697
doi: 10.1016/j.chembiol.2018.11.016
Das, U. N. Saturated fatty acids, MUFAs and PUFAs regulate ferroptosis. Cell Chem. Biol. 26, 309–311 (2019).
pubmed: 30901556
doi: 10.1016/j.chembiol.2019.03.001
Yuan, H., Li, X., Zhang, X., Kang, R. & Tang, D. Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem. Biophys. Res. Commun. 478, 1338–1343 (2016).
pubmed: 27565726
doi: 10.1016/j.bbrc.2016.08.124
Yang, Y. et al. ACSL3 and ACSL4, distinct roles in ferroptosis and cancers. Cancers 14, 5896 (2022).
pubmed: 36497375
pmcid: 9739553
doi: 10.3390/cancers14235896
Doll, S. & Conrad, M. Iron and ferroptosis: a still ill-defined liaison. IUBMB Life 69, 423–434 (2017).
pubmed: 28276141
doi: 10.1002/iub.1616
Ma, Y. et al. Long-chain Acyl-CoA synthetase 4-mediated fatty acid metabolism sustains androgen receptor pathway-independent prostate cancer. Mol. Cancer Res. 19, 124–135 (2021).
pubmed: 33077484
doi: 10.1158/1541-7786.MCR-20-0379
Marques, R. B. et al. Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS ONE 6, e23144 (2011).
pubmed: 21829708
pmcid: 3150397
doi: 10.1371/journal.pone.0023144
Wu, X. et al. ACSL4 promotes prostate cancer growth, invasion and hormonal resistance. Oncotarget 6, 44849–44863 (2015).
pubmed: 26636648
pmcid: 4792596
doi: 10.18632/oncotarget.6438
Wang, M. E. et al. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis. J. Clin. Invest. 133, e166647 (2023).
pubmed: 36928314
pmcid: 10178842
doi: 10.1172/JCI166647
Orlando, U. D. et al. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression. Biochem. Pharmacol. 159, 52–63 (2019).
pubmed: 30414939
doi: 10.1016/j.bcp.2018.11.005
Sanchez-Martinez, R., Cruz-Gil, S., Garcia-Alvarez, M. S., Reglero, G. & Ramirez de Molina, A. Complementary ACSL isoforms contribute to a non-Warburg advantageous energetic status characterizing invasive colon cancer cells. Sci. Rep. 7, 11143 (2017).
pubmed: 28894242
pmcid: 5593891
doi: 10.1038/s41598-017-11612-3
Wu, X. et al. Long chain fatty Acyl-CoA synthetase 4 is a biomarker for and mediator of hormone resistance in human breast cancer. PLoS ONE 8, e77060 (2013).
pubmed: 24155918
pmcid: 3796543
doi: 10.1371/journal.pone.0077060
Xia, H. et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib. Cell Death Discov. 3, 17058 (2017).
pubmed: 28900541
pmcid: 5592242
doi: 10.1038/cddiscovery.2017.58
Mashima, T., Seimiya, H. & Tsuruo, T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br. J. Cancer 100, 1369–1372 (2009).
pubmed: 19352381
pmcid: 2694429
doi: 10.1038/sj.bjc.6605007
Sena, L. A. & Denmeade, S. R. Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon? Cancer Res. 81, 4385–4393 (2021).
pubmed: 34145040
pmcid: 8416800
doi: 10.1158/0008-5472.CAN-21-1392
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877
doi: 10.1158/2159-8290.CD-12-0095
Swinnen, J. V., Brusselmans, K. & Verhoeven, G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 9, 358–365 (2006).
pubmed: 16778563
doi: 10.1097/01.mco.0000232894.28674.30
Swinnen, J. V., Esquenet, M., Goossens, K., Heyns, W. & Verhoeven, G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res. 57, 1086–1090 (1997).
pubmed: 9067276
Heemers, H. V., Verhoeven, G. & Swinnen, J. V. Androgen activation of the sterol regulatory element-binding protein pathway: current insights. Mol. Endocrinol. 20, 2265–2277 (2006).
pubmed: 16455816
doi: 10.1210/me.2005-0479
Butler, L. M., Centenera, M. M. & Swinnen, J. V. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications. Endocr. Relat. Cancer 23, R219–227, (2016).
pubmed: 27130044
doi: 10.1530/ERC-15-0556
Han, L. Q., Gao, T. Y., Yang, G. Y. & Loor, J. J. Overexpression of SREBF chaperone (SCAP) enhances nuclear SREBP1 translocation to upregulate fatty acid synthase (FASN) gene expression in bovine mammary epithelial cells. J. Dairy. Sci. 101, 6523–6531 (2018).
pubmed: 29680640
doi: 10.3168/jds.2018-14382
Rossi, S. et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res. 1, 707–715 (2003).
pubmed: 12939396
Shah, U. S. et al. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma. Hum. Pathol. 37, 401–409 (2006).
pubmed: 16564913
doi: 10.1016/j.humpath.2005.11.022
Epstein, J. I., Carmichael, M. & Partin, A. W. OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate. Urology 45, 81–86 (1995).
pubmed: 7817483
doi: 10.1016/S0090-4295(95)96904-7
Song, X. et al. PDK4 dictates metabolic resistance to ferroptosis by suppressing pyruvate oxidation and fatty acid synthesis. Cell Rep. 34, 108767 (2021).
pubmed: 33626342
doi: 10.1016/j.celrep.2021.108767
Li, C. et al. LKB1-AMPK axis negatively regulates ferroptosis by inhibiting fatty acid synthesis. Signal. Transduct. Target. Ther. 5, 187 (2020).
pubmed: 32883948
pmcid: 7471309
doi: 10.1038/s41392-020-00297-2
Lee, H. et al. Energy-stress-mediated AMPK activation inhibits ferroptosis. Nat. Cell Biol. 22, 225–234 (2020).
pubmed: 32029897
pmcid: 7008777
doi: 10.1038/s41556-020-0461-8
Bartolacci, C. et al. Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat. Commun. 13, 4327 (2022).
pubmed: 35882862
pmcid: 9325712
doi: 10.1038/s41467-022-31963-4
Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251–262 (2012).
pubmed: 22436748
pmcid: 5726489
doi: 10.1038/nrm3311
Park, H. U. et al. AMP-activated protein kinase promotes human prostate cancer cell growth and survival. Mol. Cancer Ther. 8, 733–741 (2009).
pubmed: 19372545
pmcid: 2775041
doi: 10.1158/1535-7163.MCT-08-0631
Tennakoon, J. B. et al. Androgens regulate prostate cancer cell growth via an AMPK-PGC-1ɑ-mediated metabolic switch. Oncogene 33, 5251–5261 (2014).
pubmed: 24186207
doi: 10.1038/onc.2013.463
Lin, C. et al. Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. Oncogene 40, 1690–1705 (2021).
pubmed: 33531625
pmcid: 7935762
doi: 10.1038/s41388-021-01658-z
Khan, A. S. & Frigo, D. E. A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer. Nat. Rev. Urol. 14, 164–180 (2017).
pubmed: 28169991
pmcid: 5672799
doi: 10.1038/nrurol.2016.272
Frigo, D. E. et al. CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res. 71, 528–537 (2011).
pubmed: 21098087
doi: 10.1158/0008-5472.CAN-10-2581
Enoch, H. G., Catala, A. & Strittmatter, P. Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies of the substrate specificity, enzyme-substrate interactions, and the function of lipid. J. Biol. Chem. 251, 5095–5103 (1976).
pubmed: 8453
doi: 10.1016/S0021-9258(17)33223-4
Amezaga, J. et al. Altered red blood cell membrane fatty acid profile in cancer patients. Nutrients 10, 1853 (2018).
pubmed: 30513730
pmcid: 6315925
doi: 10.3390/nu10121853
Chavarro, J. E. et al. Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer. Am. J. Epidemiol. 178, 1246–1255 (2013).
pubmed: 23989197
pmcid: 3792734
doi: 10.1093/aje/kwt136
Fritz, V. et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol. Cancer Ther. 9, 1740–1754 (2010).
pubmed: 20530718
pmcid: 3315476
doi: 10.1158/1535-7163.MCT-09-1064
Yi, J., Zhu, J., Wu, J., Thompson, C. B. & Jiang, X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc. Natl Acad. Sci. USA 117, 31189–31197 (2020).
pubmed: 33229547
pmcid: 7733797
doi: 10.1073/pnas.2017152117
Tesfay, L. et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 79, 5355–5366 (2019).
pubmed: 31270077
pmcid: 6801059
doi: 10.1158/0008-5472.CAN-19-0369
Kagan, V. E. et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat. Chem. Biol. 13, 81–90 (2017).
pubmed: 27842066
doi: 10.1038/nchembio.2238
D’Angelo, S., Motti, M. L. & Meccariello, R. ω-3 and ω-6 polyunsaturated fatty acids, obesity and cancer. Nutrients 12, 2751 (2020).
pubmed: 32927614
pmcid: 7551151
doi: 10.3390/nu12092751
Lee, J. M., Lee, H., Kang, S. & Park, W. J. Fatty acid desaturases, polyunsaturated fatty acid regulation, and biotechnological advances. Nutrients 8, 23 (2016).
pubmed: 26742061
pmcid: 4728637
doi: 10.3390/nu8010023
Lee, J. Y. et al. Polyunsaturated fatty acid biosynthesis pathway determines ferroptosis sensitivity in gastric cancer. Proc. Natl Acad. Sci. USA 117, 32433–32442 (2020).
pubmed: 33288688
pmcid: 7768719
doi: 10.1073/pnas.2006828117
Yamane, D. et al. FADS2-dependent fatty acid desaturation dictates cellular sensitivity to ferroptosis and permissiveness for hepatitis C virus replication. Cell Chem. Biol. 29, 799–810 e794 (2022).
pubmed: 34520742
doi: 10.1016/j.chembiol.2021.07.022
Xu, H. et al. ELOVL5-mediated long chain fatty acid elongation contributes to enzalutamide resistance of prostate cancer. Cancers 13, 3957 (2021).
pubmed: 34439125
pmcid: 8391805
doi: 10.3390/cancers13163957
Centenera, M. M. et al. ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer. Cancer Res. 81, 1704–1718 (2021).
pubmed: 33547161
doi: 10.1158/0008-5472.CAN-20-2511
Schlaepfer, I. R. & Joshi, M. CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential. Endocrinology 161, bqz046 (2020).
pubmed: 31900483
doi: 10.1210/endocr/bqz046
Flaig, T. W. et al. Lipid catabolism inhibition sensitizes prostate cancer cells to antiandrogen blockade. Oncotarget 8, 56051–56065 (2017).
pubmed: 28915573
pmcid: 5593544
doi: 10.18632/oncotarget.17359
Joshi, M. et al. CPT1A supports castration-resistant prostate cancer in androgen-deprived conditions. Cells 8, 115 (2019).
doi: 10.3390/cells8101115
Nassar, Z. D. et al. Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis. Elife 9, e54166 (2020).
pubmed: 32686647
pmcid: 7386908
doi: 10.7554/eLife.54166
Gao, M., Monian, P., Quadri, N., Ramasamy, R. & Jiang, X. Glutaminolysis and transferrin regulate ferroptosis. Mol. Cell 59, 298–308 (2015).
pubmed: 26166707
pmcid: 4506736
doi: 10.1016/j.molcel.2015.06.011
Philpott, C. C. et al. Iron-tracking strategies: chaperones capture iron in the cytosolic labile iron pool. Front. Mol. Biosci. 10, 1127690 (2023).
pubmed: 36818045
pmcid: 9932599
doi: 10.3389/fmolb.2023.1127690
Yanatori, I., Richardson, D. R., Imada, K. & Kishi, F. Iron export through the transporter ferroportin 1 is modulated by the iron chaperone PCBP2. J. Biol. Chem. 291, 17303–17318 (2016).
pubmed: 27302059
pmcid: 5016129
doi: 10.1074/jbc.M116.721936
Donovan, A. et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1, 191–200 (2005).
pubmed: 16054062
doi: 10.1016/j.cmet.2005.01.003
Nemeth, E. & Ganz, T. The role of hepcidin in iron metabolism. Acta Haematol. 122, 78–86 (2009).
pubmed: 19907144
pmcid: 2855274
doi: 10.1159/000243791
Hubert, N. & Hentze, M. W. Previously uncharacterized isoforms of divalent metal transporter (DMT)-1: implications for regulation and cellular function. Proc. Natl Acad. Sci. USA 99, 12345–12350 (2002).
pubmed: 12209011
pmcid: 129447
doi: 10.1073/pnas.192423399
Dai, E., Meng, L., Kang, R., Wang, X. & Tang, D. ESCRT-III-dependent membrane repair blocks ferroptosis. Biochem. Biophys. Res. Commun. 522, 415–421 (2020).
pubmed: 31761326
doi: 10.1016/j.bbrc.2019.11.110
Vela, D. Iron metabolism in prostate cancer; from basic science to new therapeutic strategies. Front. Oncol. 8, 547 (2018).
pubmed: 30538952
pmcid: 6277552
doi: 10.3389/fonc.2018.00547
Torti, S. V., Manz, D. H., Paul, B. T., Blanchette-Farra, N. & Torti, F. M. Iron and cancer. Annu. Rev. Nutr. 38, 97–125 (2018).
pubmed: 30130469
pmcid: 8118195
doi: 10.1146/annurev-nutr-082117-051732
Brown, R. A. M. et al. Altered iron metabolism and impact in cancer biology, metastasis, and immunology. Front. Oncol. 10, 476 (2020).
pubmed: 32328462
pmcid: 7160331
doi: 10.3389/fonc.2020.00476
Deng, Z., Manz, D. H., Torti, S. V. & Torti, F. M. Iron-responsive element-binding protein 2 plays an essential role in regulating prostate cancer cell growth. Oncotarget 8, 82231–82243 (2017).
pubmed: 29137259
pmcid: 5669885
doi: 10.18632/oncotarget.19288
Keer, H. N. et al. Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J. Urol. 143, 381–385 (1990).
pubmed: 1688956
doi: 10.1016/S0022-5347(17)39970-6
Kuvibidila, S., Gauthier, T., Warrier, R. P. & Rayford, W. Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores. J. Lab. Clin. Med. 144, 176–182 (2004).
pubmed: 15514585
doi: 10.1016/j.lab.2004.03.017
Xue, D., Zhou, C. X., Shi, Y. B., Lu, H. & He, X. Z. Decreased expression of ferroportin in prostate cancer. Oncol. Lett. 10, 913–916 (2015).
pubmed: 26622594
pmcid: 4509077
doi: 10.3892/ol.2015.3363
Burnell, S. E. A. et al. STEAP2 knockdown reduces the invasive potential of prostate cancer cells. Sci. Rep. 8, 6252 (2018).
pubmed: 29674723
pmcid: 5908900
doi: 10.1038/s41598-018-24655-x
Hou, W. et al. Autophagy promotes ferroptosis by degradation of ferritin. Autophagy 12, 1425–1428 (2016).
pubmed: 27245739
pmcid: 4968231
doi: 10.1080/15548627.2016.1187366
Winterbourn, C. C. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol. Lett. 82-83, 969–974 (1995).
pubmed: 8597169
doi: 10.1016/0378-4274(95)03532-X
Dhur, A., Galan, P. & Hercberg, S. Effects of different degrees of iron deficiency on cytochrome P450 complex and pentose phosphate pathway dehydrogenases in the rat. J. Nutr. 119, 40–47 (1989).
pubmed: 2492336
doi: 10.1093/jn/119.1.40
Pistorius, E. K. & Axelrod, B. Iron, an essential component of lipoxygenase. J. Biol. Chem. 249, 3183–3186 (1974).
pubmed: 4364417
doi: 10.1016/S0021-9258(19)42656-2
Yauger, Y. J. et al. Iron accentuated reactive oxygen species release by NADPH oxidase in activated microglia contributes to oxidative stress in vitro. J. Neuroinflammation 16, 41 (2019).
pubmed: 30777083
pmcid: 6378754
doi: 10.1186/s12974-019-1430-7
Bordini, J. et al. Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma. Leukemia 31, 967–970 (2017).
pubmed: 27881873
doi: 10.1038/leu.2016.346
Campanella, A. et al. Iron increases the susceptibility of multiple myeloma cells to bortezomib. Haematologica 98, 971–979 (2013).
pubmed: 23242599
pmcid: 3669455
doi: 10.3324/haematol.2012.074872
Bordini, J. et al. Iron induces cell death and strengthens the efficacy of antiandrogen therapy in prostate cancer models. Clin. Cancer Res. 26, 6387–6398 (2020).
pubmed: 32928793
doi: 10.1158/1078-0432.CCR-20-3182
Maccarinelli, F. et al. Iron supplementation enhances RSL3-induced ferroptosis to treat naive and prevent castration-resistant prostate cancer. Cell Death Discov. 9, 81 (2023).
pubmed: 36872341
pmcid: 9986230
doi: 10.1038/s41420-023-01383-4
Liu, Y. et al. Liposomes embedded with PEGylated iron oxide nanoparticles enable ferroptosis and combination therapy in cancer. Natl Sci. Rev. 10, nwac167 (2023).
pubmed: 36684514
doi: 10.1093/nsr/nwac167
Fernandez-Acosta, R. et al. Novel iron oxide nanoparticles induce ferroptosis in a panel of cancer cell lines. Molecules 27, 3970 (2022).
pubmed: 35807217
pmcid: 9268471
doi: 10.3390/molecules27133970
Bonvin, D. et al. Tuning properties of iron oxide nanoparticles in aqueous synthesis without ligands to improve MRI relaxivity and SAR. Nanomaterials 7, 225 (2017).
pubmed: 28820442
pmcid: 5575707
doi: 10.3390/nano7080225
Hajikarimi, Z., Khoei, S., Khoee, S. & Mahdavi, S. R. Evaluation of the cytotoxic effects of PLGA coated iron oxide nanoparticles as a carrier of 5- fluorouracil and mega-voltage X-ray radiation in DU145 prostate cancer cell line. IEEE Trans. Nanobiosci. 13, 403–408 (2014).
doi: 10.1109/TNB.2014.2328868
Kader, A. et al. Iron oxide nanoparticles for visualization of prostate cancer in MRI. Cancers 14, 2909 (2022).
pubmed: 35740575
pmcid: 9221397
doi: 10.3390/cancers14122909
Cluntun, A. A., Lukey, M. J., Cerione, R. A. & Locasale, J. W. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer 3, 169–180 (2017).
pubmed: 28393116
pmcid: 5383348
doi: 10.1016/j.trecan.2017.01.005
Gong, T. et al. Glutamine metabolism in cancers: targeting the oxidative homeostasis. Front. Oncol. 12, 994672 (2022).
pubmed: 36324588
pmcid: 9621616
doi: 10.3389/fonc.2022.994672
Wang, Q. et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J. Pathol. 236, 278–289 (2015).
pubmed: 25693838
pmcid: 4973854
doi: 10.1002/path.4518
Wang, Q. et al. Androgen receptor and nutrient signaling pathways coordinate the demand for increased amino acid transport during prostate cancer progression. Cancer Res. 71, 7525–7536 (2011).
pubmed: 22007000
doi: 10.1158/0008-5472.CAN-11-1821
Cardoso, H. J. et al. Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5ɑ-dihydrotestosterone regulation. Cell Oncol. 44, 385–403 (2021).
doi: 10.1007/s13402-020-00575-9
Serpa, J. Cysteine as a carbon source, a hot spot in cancer cells survival. Front. Oncol. 10, 947 (2020).
pubmed: 32714858
pmcid: 7344258
doi: 10.3389/fonc.2020.00947
Poltorack, C. D. & Dixon, S. J. Understanding the role of cysteine in ferroptosis: progress & paradoxes. FEBS J. 289, 374–385 (2022).
pubmed: 33773039
doi: 10.1111/febs.15842
Yang, J., Dai, X., Xu, H., Tang, Q. & Bi, F. Regulation of ferroptosis by amino acid metabolism in cancer. Int. J. Biol. Sci. 18, 1695–1705 (2022).
pubmed: 35280684
pmcid: 8898355
doi: 10.7150/ijbs.64982
Zhong, W. et al. Extracellular redox state shift: a novel approach to target prostate cancer invasion. Free. Radic. Biol. Med. 117, 99–109 (2018).
pubmed: 29421238
pmcid: 5845758
doi: 10.1016/j.freeradbiomed.2018.01.023
Doxsee, D. W. et al. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67, 162–171 (2007).
pubmed: 17075799
doi: 10.1002/pros.20508
Cramer, S. L. et al. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth. Nat. Med. 23, 120–127 (2017).
pubmed: 27869804
doi: 10.1038/nm.4232
Mandigo, A. C. et al. RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. Cancer Discov. 11, 2334–2353 (2021).
pubmed: 33879449
pmcid: 8419081
doi: 10.1158/2159-8290.CD-20-1114
Nikfar, S., Rahimi, R., Rezaie, A. & Abdollahi, M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig. Dis. Sci. 54, 1157–1170 (2009).
pubmed: 18770034
doi: 10.1007/s10620-008-0481-x
Rains, C. P., Noble, S. & Faulds, D. Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis. Drugs 50, 137–156 (1995).
pubmed: 7588084
doi: 10.2165/00003495-199550010-00009
Kavallaris, M. Microtubules and resistance to tubulin-binding agents. Nat. Rev. Cancer 10, 194–204 (2010).
pubmed: 20147901
doi: 10.1038/nrc2803
Ogura, T., Tanaka, Y., Tamaki, H. & Harada, M. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells. Int. J. Oncol. 48, 2330–2338 (2016).
pubmed: 27082738
pmcid: 4864052
doi: 10.3892/ijo.2016.3482
Darshan, M. S. et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71, 6019–6029 (2011).
pubmed: 21799031
pmcid: 3354631
doi: 10.1158/0008-5472.CAN-11-1417
de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
pubmed: 20888992
doi: 10.1016/S0140-6736(10)61389-X
Galsky, M. D., Dritselis, A., Kirkpatrick, P. & Oh, W. K. Cabazitaxel. Nat. Rev. Drug. Discov. 9, 677–678 (2010).
pubmed: 20811375
doi: 10.1038/nrd3254
Chen, X. et al. Ferroptosis induction improves the sensitivity of docetaxel in prostate cancer. Oxid. Med. Cell. Longev. 2022, 1–16 (2022).
Jiang, X. et al. TFAP2C-mediated lncRNA PCAT1 inhibits ferroptosis in docetaxel-resistant prostate cancer through c-Myc/miR-25-3p/SLC7A11 signaling. Front. Oncol. 12, 862015 (2022).
pubmed: 35402284
pmcid: 8985761
doi: 10.3389/fonc.2022.862015
He, S. et al. ChaC glutathione specific γ-glutamylcyclotransferase 1 inhibits cell viability and increases the sensitivity of prostate cancer cells to docetaxel by inducing endoplasmic reticulum stress and ferroptosis. Exp. Ther. Med. 22, 997 (2021).
pubmed: 34345279
pmcid: 8311285
doi: 10.3892/etm.2021.10429
Ogawa, T. et al. CHAC1 overexpression in human gastric parietal cells with Helicobacter pylori infection in the secretory canaliculi. Helicobacter 24, e12598 (2019).
pubmed: 31111570
pmcid: 6618068
doi: 10.1111/hel.12598
Takeda, D. Y. et al. A somatically acquired enhancer of the androgen receptor is a noncoding driver in advanced prostate cancer. Cell 174, 422–432 e413 (2018).
pubmed: 29909987
pmcid: 6046260
doi: 10.1016/j.cell.2018.05.037
Schweizer, M. T. & Yu, E. Y. Persistent androgen receptor addiction in castration-resistant prostate cancer. J. Hematol. Oncol. 8, 128 (2015).
pubmed: 26566796
pmcid: 4644296
doi: 10.1186/s13045-015-0225-2
Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).
pubmed: 31061129
pmcid: 6561293
doi: 10.1073/pnas.1902651116
Watson, P. A., Arora, V. K. & Sawyers, C. L. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat. Rev. Cancer 15, 701–711 (2015).
pubmed: 26563462
pmcid: 4771416
doi: 10.1038/nrc4016
Cattrini, C. et al. Apalutamide, darolutamide and enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC): a critical review. Cancers 14, 1492 (2022).
doi: 10.3390/cancers14071792
Desai, K., McManus, J. M. & Sharifi, N. Hormonal therapy for prostate cancer. Endocr. Rev. 42, 354–373 (2021).
pubmed: 33480983
pmcid: 8152444
doi: 10.1210/endrev/bnab002
Clarke, N. W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 1, EVIDoa2200043 (2022).
pubmed: 38319800
doi: 10.1056/EVIDoa2200043
Chi, K. N. et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 41, 3339–3351 (2023).
pubmed: 36952634
pmcid: 10431499
doi: 10.1200/JCO.22.01649
Hong, T. et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 42, 101928 (2021).
pubmed: 33722571
pmcid: 8113041
doi: 10.1016/j.redox.2021.101928
Sugiura, M. et al. Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer. Transl. Oncol. 14, 100915 (2021).
pubmed: 33096335
doi: 10.1016/j.tranon.2020.100915
Yang, F. et al. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 35, 84–100.e8 (2023).
pubmed: 36257316
doi: 10.1016/j.cmet.2022.09.021
Sun, R. et al. Androgen receptor variants confer castration resistance in prostate cancer by counteracting antiandrogen-induced ferroptosis. Cancer Res. 83, 3192–3204 (2023).
pubmed: 37527336
pmcid: 10543964
doi: 10.1158/0008-5472.CAN-23-0285
Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell 186, 2748–2764 e2722 (2023).
pubmed: 37267948
doi: 10.1016/j.cell.2023.05.003
Ma, D. et al. Crystal structure of a membrane-bound O-acyltransferase. Nature 562, 286–290 (2018).
pubmed: 30283133
pmcid: 6529733
doi: 10.1038/s41586-018-0568-2
Masumoto, N. et al. Membrane bound O-acyltransferases and their inhibitors. Biochem. Soc. Trans. 43, 246–252 (2015).
pubmed: 25849925
doi: 10.1042/BST20150018
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
doi: 10.1056/NEJMoa1003466
Runcie, K. D. & Dallos, M. C. Prostate cancer immunotherapy — finally in from the cold? Curr. Oncol. Rep. 23, 88 (2021).
pubmed: 34125308
doi: 10.1007/s11912-021-01084-0
Graff, J. N. et al. Phase II study of ipilimumab in men with metastatic prostate cancer with an incomplete response to androgen deprivation therapy. Front. Oncol. 10, 1381 (2020).
pubmed: 32850444
pmcid: 7426513
doi: 10.3389/fonc.2020.01381
Fizazi, K. et al. Final analysis of the ipilimumab versus placebo following radiotherapy phase III trial in postdocetaxel metastatic castration-resistant prostate cancer identifies an excess of long-term survivors. Eur. Urol. 78, 822–830 (2020).
pubmed: 32811715
pmcid: 8428575
doi: 10.1016/j.eururo.2020.07.032
Cabel, L. et al. Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients. J. Immunother. Cancer 5, 31 (2017).
pubmed: 28428880
pmcid: 5394619
doi: 10.1186/s40425-017-0232-7
Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkmate 650 trial. Cancer Cell 38, 489–499 e483 (2020).
pubmed: 32916128
doi: 10.1016/j.ccell.2020.08.007
Fizazi, K. et al. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. J. Immunother. Cancer 10, e004761 (2022).
pubmed: 35977756
pmcid: 9389086
doi: 10.1136/jitc-2022-004761
Fizazi, K. et al. Nivolumab plus docetaxel in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. Eur. J. Cancer 160, 61–71 (2022).
pubmed: 34802864
doi: 10.1016/j.ejca.2021.09.043
Petrylak, D. P. et al. KEYNOTE-921: phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 17, 3291–3299 (2021).
pubmed: 34098744
doi: 10.2217/fon-2020-1133
Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395–405 (2020).
pubmed: 31774688
doi: 10.1200/JCO.19.01638
Petrylak, D. P. et al. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a phase I study. Clin. Cancer Res. 27, 3360–3369 (2021).
pubmed: 33568344
doi: 10.1158/1078-0432.CCR-20-1981
Powles, T. et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat. Med. 28, 144–153 (2022).
pubmed: 35013615
pmcid: 9406237
doi: 10.1038/s41591-021-01600-6
Rodriguez-Vida, A. et al. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. Br. J. Cancer 128, 21–29 (2023).
pubmed: 36289372
doi: 10.1038/s41416-022-01991-4
Kwan, E. M. et al. Avelumab combined with stereotactic ablative body radiotherapy in metastatic castration-resistant prostate cancer: the phase 2 ICE-PAC clinical trial. Eur. Urol. 81, 253–262 (2022).
pubmed: 34493414
doi: 10.1016/j.eururo.2021.08.011
Karzai, F. et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer 6, 141 (2018).
pubmed: 30514390
pmcid: 6280368
doi: 10.1186/s40425-018-0463-2
Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
pubmed: 20818862
doi: 10.1056/NEJMoa1001294
Shore, N. D. et al. CD8
pubmed: 32208168
pmcid: 7210698
doi: 10.1016/j.ymthe.2020.02.018
Kyriakopoulos, C. E. et al. Multicenter phase I trial of a DNA vaccine encoding the androgen receptor ligand-binding domain (pTVG-AR, MVI-118) in patients with metastatic prostate cancer. Clin. Cancer Res. 26, 5162–5171 (2020).
pubmed: 32513836
pmcid: 7541575
doi: 10.1158/1078-0432.CCR-20-0945
Singh, P., Pal, S. K., Alex, A. & Agarwal, N. Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol. 11, 2137–2148 (2015).
pubmed: 26235179
doi: 10.2217/fon.15.120
Gulley, J. L. et al. Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. J. Clin. Oncol. 37, 1051–1061 (2019).
pubmed: 30817251
pmcid: 6494360
doi: 10.1200/JCO.18.02031
van den Eertwegh, A. J. et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13, 509–517 (2012).
pubmed: 22326922
doi: 10.1016/S1470-2045(12)70007-4
Small, E. J. et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 13, 3883–3891 (2007).
pubmed: 17606721
doi: 10.1158/1078-0432.CCR-06-2937
Higano, C. S. et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 113, 975–984 (2008).
pubmed: 18646045
doi: 10.1002/cncr.23669
Tschernia, N. P., Norberg, S. M. & Gulley, J. L. CAR T cells reach clinical milestone in prostate cancer. Nat. Med. 28, 635–636 (2022).
pubmed: 35314844
doi: 10.1038/s41591-022-01742-1
Perera, M. P. J. et al. Chimeric antigen receptor T-cell therapy in metastatic castrate-resistant prostate cancer. Cancers 14, 503 (2022).
pubmed: 35158771
pmcid: 8833489
doi: 10.3390/cancers14030503
Narayan, V. et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 28, 724–734 (2022).
pubmed: 35314843
pmcid: 10308799
doi: 10.1038/s41591-022-01726-1
Yunger, S. et al. Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy. Oncoimmunology 8, e1672494 (2019).
pubmed: 31741775
pmcid: 6844325
doi: 10.1080/2162402X.2019.1672494
Karbach, J. et al. Tumor-infiltrating lymphocytes mediate complete and durable remission in a patient with NY-ESO-1 expressing prostate cancer. J. Immunother. Cancer 11, e005847 (2023).
pubmed: 36627144
pmcid: 9835940
doi: 10.1136/jitc-2022-005847
Kamat, N. V., Yu, E. Y. & Lee, J. K. BiTE-ing into prostate cancer with bispecific T-cell engagers. Clin. Cancer Res. 27, 2675–2677 (2021).
pubmed: 33707179
pmcid: 8127346
doi: 10.1158/1078-0432.CCR-21-0355
Hummel, H. D. et al. Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings. Immunotherapy 13, 125–141 (2021).
pubmed: 33172323
doi: 10.2217/imt-2020-0256
Wang, W. et al. CD8
pubmed: 31043744
pmcid: 6533917
doi: 10.1038/s41586-019-1170-y
Liao, P. et al. CD8
pubmed: 35216678
pmcid: 9007863
doi: 10.1016/j.ccell.2022.02.003
Jiang, Z. et al. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J. Clin. Invest. 131, e139434 (2021).
pubmed: 33855973
pmcid: 8262501
doi: 10.1172/JCI139434
Efimova, I. et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J. Immunother. Cancer 8, e001369 (2020).
pubmed: 33188036
pmcid: 7668384
doi: 10.1136/jitc-2020-001369
Tang, D., Kepp, O. & Kroemer, G. Ferroptosis becomes immunogenic: implications for anticancer treatments. Oncoimmunology 10, 1862949 (2020).
pubmed: 33457081
pmcid: 7781761
doi: 10.1080/2162402X.2020.1862949
Wen, Q., Liu, J., Kang, R., Zhou, B. & Tang, D. The release and activity of HMGB1 in ferroptosis. Biochem. Biophys. Res. Commun. 510, 278–283 (2019).
pubmed: 30686534
doi: 10.1016/j.bbrc.2019.01.090
Yu, B., Choi, B., Li, W. & Kim, D. H. Magnetic field boosted ferroptosis-like cell death and responsive MRI using hybrid vesicles for cancer immunotherapy. Nat. Commun. 11, 3637 (2020).
pubmed: 32686685
pmcid: 7371635
doi: 10.1038/s41467-020-17380-5
Wu, Z. et al. The landscape of immune cells infiltrating in prostate cancer. Front. Oncol. 10, 517637 (2020).
pubmed: 33194581
pmcid: 7658630
doi: 10.3389/fonc.2020.517637
Martin, A. M. et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 18, 325–332 (2015).
pubmed: 26260996
pmcid: 4641011
doi: 10.1038/pcan.2015.39
Matsushita, M. et al. T cell lipid peroxidation induces ferroptosis and prevents immunity to infection. J. Exp. Med. 212, 555–568 (2015).
pubmed: 25824823
pmcid: 4387287
doi: 10.1084/jem.20140857
Ma, X. et al. CD36-mediated ferroptosis dampens intratumoral CD8
pubmed: 33691090
pmcid: 8102368
doi: 10.1016/j.cmet.2021.02.015
Zhou, X. et al. Abrogation of HnRNP L enhances anti-PD-1 therapy efficacy via diminishing PD-L1 and promoting CD8
pubmed: 35256940
doi: 10.1016/j.apsb.2021.07.016
Sindhu, K. K., Nehlsen, A. D. & Stock, R. G. Radium-223 for metastatic castrate-resistant prostate cancer. Pract. Radiat. Oncol. 12, 312–316 (2022).
pubmed: 35717046
doi: 10.1016/j.prro.2022.03.004
Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213–223 (2013).
pubmed: 23863050
doi: 10.1056/NEJMoa1213755
Violet, J. et al. Dosimetry of
pubmed: 30291192
doi: 10.2967/jnumed.118.219352
Sun, M., Niaz, M. O., Nelson, A., Skafida, M. & Niaz, M. J. Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Cureus 12, e8921 (2020).
pubmed: 32760622
pmcid: 7392183
Schuchardt, C. et al. Prostate-specific membrane antigen radioligand therapy using
pubmed: 34887335
pmcid: 9364353
doi: 10.2967/jnumed.121.262713
Kratochwil, C. et al. 225Ac-PSMA-617 for PSMA-targeted ɑ-radiation therapy of metastatic castration-resistant prostate cancer. J. Nucl. Med. 57, 1941–1944 (2016).
pubmed: 27390158
doi: 10.2967/jnumed.116.178673
Hammer, S. et al. Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted ɑ therapy for prostate cancer. Clin. Cancer Res. 26, 1985–1996 (2020).
pubmed: 31831560
doi: 10.1158/1078-0432.CCR-19-2268
Kiess, A. P. et al. 2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-pentanedioic acid for PSMA-targeted ɑ-particle radiopharmaceutical therapy. J. Nucl. Med. 57, 1569–1575 (2016).
pubmed: 27230930
pmcid: 5367442
doi: 10.2967/jnumed.116.174300
Ye, L. F. et al. Radiation-induced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers. ACS Chem. Biol. 15, 469–484 (2020).
pubmed: 31899616
pmcid: 7180072
doi: 10.1021/acschembio.9b00939
Lang, X. et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11. Cancer Discov. 9, 1673–1685 (2019).
pubmed: 31554642
pmcid: 6891128
doi: 10.1158/2159-8290.CD-19-0338
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847–849 (1993).
pubmed: 8479522
doi: 10.1038/362847a0
Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304–6311 (1991).
pubmed: 1933891
Jiang, L. et al. Ferroptosis as a p53-mediated activity during tumour suppression. Nature 520, 57–62 (2015).
pubmed: 25799988
pmcid: 4455927
doi: 10.1038/nature14344
Wang, Y. et al. Epigenetic regulation of ferroptosis by H2B monoubiquitination and p53. EMBO Rep. 20, e47563 (2019).
pubmed: 31267712
pmcid: 6607012
doi: 10.15252/embr.201847563
Shen, D. et al. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer. Cancer Lett. 550, 215919 (2022).
pubmed: 36116741
doi: 10.1016/j.canlet.2022.215919
Lei, G., Mao, C., Yan, Y., Zhuang, L. & Gan, B. Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell 12, 836–857 (2021).
pubmed: 33891303
pmcid: 8563889
doi: 10.1007/s13238-021-00841-y
Beretta, G. L. & Zaffaroni, N. Radiotherapy-induced ferroptosis for cancer treatment. Front. Mol. Biosci. 10, 1216733 (2023).
pubmed: 37388241
pmcid: 10304297
doi: 10.3389/fmolb.2023.1216733
Upadhyayula, P. S. et al. Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism. Nat. Commun. 14, 1187 (2023).
pubmed: 36864031
pmcid: 9981683
doi: 10.1038/s41467-023-36630-w
Xue, Y. et al. Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade. Nat. Commun. 14, 4758 (2023).
pubmed: 37553341
pmcid: 10409767
doi: 10.1038/s41467-023-40518-0
Dierge, E. et al. Peroxidation of n-3 and n-6 polyunsaturated fatty acids in the acidic tumor environment leads to ferroptosis-mediated anticancer effects. Cell Metab. 33, 1701–1715 e1705 (2021).
pubmed: 34118189
doi: 10.1016/j.cmet.2021.05.016
Ferrer, M. et al. Ketogenic diet promotes tumor ferroptosis but induces relative corticosterone deficiency that accelerates cachexia. Cell Metab. 35, 1147–1162 e1147 (2023).
pubmed: 37311455
doi: 10.1016/j.cmet.2023.05.008
Pissios, P. et al. Methionine and choline regulate the metabolic phenotype of a ketogenic diet. Mol. Metab. 2, 306–313 (2013).
pubmed: 24049742
pmcid: 3773836
doi: 10.1016/j.molmet.2013.07.003
Eaton, J. K. et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles. Nat. Chem. Biol. 16, 497–506 (2020).
pubmed: 32231343
pmcid: 7251976
doi: 10.1038/s41589-020-0501-5
Eaton, J. K., Ruberto, R. A., Kramm, A., Viswanathan, V. S. & Schreiber, S. L. Diacylfuroxans are masked nitrile oxides that inhibit GPX4 covalently. J. Am. Chem. Soc. 141, 20407–20415 (2019).
pubmed: 31841309
doi: 10.1021/jacs.9b10769
Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317–331 (2014).
pubmed: 24439385
pmcid: 4076414
doi: 10.1016/j.cell.2013.12.010
Koppula, P. et al. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers. Nat. Commun. 13, 2206 (2022).
pubmed: 35459868
pmcid: 9033817
doi: 10.1038/s41467-022-29905-1
Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693–698 (2019).
pubmed: 31634899
doi: 10.1038/s41586-019-1707-0
Xavier da Silva, T. N., Schulte, C., Alves, A. N., Maric, H. M. & Friedmann Angeli, J. P. Molecular characterization of AIFM2/FSP1 inhibition by iFSP1-like molecules. Cell Death Dis. 14, 281 (2023).
pubmed: 37080964
pmcid: 10119282
doi: 10.1038/s41419-023-05787-z
Hendricks, J. M. et al. Identification of structurally diverse FSP1 inhibitors that sensitize cancer cells to ferroptosis. Cell Chem. Biol. 30, 1090–1103 e1097 (2023).
pubmed: 37178691
doi: 10.1016/j.chembiol.2023.04.007
Yoshioka, H. et al. Identification of a small molecule that enhances ferroptosis via inhibition of ferroptosis suppressor protein 1 (FSP1). ACS Chem. Biol. 17, 483–491 (2022).
pubmed: 35128925
doi: 10.1021/acschembio.2c00028
Antoszczak, M. & Huczynski, A. Salinomycin and its derivatives — a new class of multiple-targeted “magic bullets”. Eur. J. Med. Chem. 176, 208–227 (2019).
pubmed: 31103901
doi: 10.1016/j.ejmech.2019.05.031
Miyazaki, Y., Shibuya, M., Sugawara, H., Kawaguchi, O. & Hirsoe, C. Salinomycin, a new polyether antibiotic. J. Antibiot. 27, 814–821 (1974).
doi: 10.7164/antibiotics.27.814
Zhou, S. et al. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. Curr. Med. Chem. 20, 4095–4101 (2013).
pubmed: 23931281
pmcid: 4102832
doi: 10.2174/15672050113109990199
Mai, T. T. et al. Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat. Chem. 9, 1025–1033 (2017).
pubmed: 28937680
pmcid: 5890907
doi: 10.1038/nchem.2778
Mohammad, A. et al. Abstract 3107: HSB-1216, a novel agent for the treatment of chemotherapy-resistant ES-SCLC. Cancer Res. 81, 3107–3107 (2021).
doi: 10.1158/1538-7445.AM2021-3107
Kharbanda, S. et al. Novel iron-mediated cell death (Ferroptosis) inducer, HSB-1216, suppress acute myeloid leukemia growth. Eur. J. Cancer https://doi.org/10.1016/s0959-8049(22)00936-4 (2022).
Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).
pubmed: 32015325
pmcid: 6997353
doi: 10.1038/s41419-020-2298-2
Kloditz, K. & Fadeel, B. Three cell deaths and a funeral: macrophage clearance of cells undergoing distinct modes of cell death. Cell Death Discov. 5, 65 (2019).
pubmed: 30774993
pmcid: 6368547
doi: 10.1038/s41420-019-0146-x
Zou, Y. & Schreiber, S. L. Progress in understanding ferroptosis and challenges in its targeting for therapeutic benefit. Cell Chem. Biol. 27, 463–471 (2020).
pubmed: 32302583
pmcid: 7346472
doi: 10.1016/j.chembiol.2020.03.015
Li, Z. et al. In vivo tracking cystine/glutamate antiporter-mediated cysteine/cystine pool under ferroptosis. Anal. Chim. Acta 1125, 66–75 (2020).
pubmed: 32674782
doi: 10.1016/j.aca.2020.05.049
Li, Z. Imaging of hydrogen peroxide (H(2)O(2)) during the ferroptosis process in living cancer cells with a practical fluorescence probe. Talanta 212, 120804 (2020).
pubmed: 32113566
doi: 10.1016/j.talanta.2020.120804
Conrad, M. & Pratt, D. A. The chemical basis of ferroptosis. Nat. Chem. Biol. 15, 1137–1147 (2019).
pubmed: 31740834
doi: 10.1038/s41589-019-0408-1
Zeng, F. et al. Ferroptosis detection: from approaches to applications. Angew. Chem. Int. Ed. 62, e202300379 (2023).
doi: 10.1002/anie.202300379
Li, J., Kang, R. & Tang, D. Monitoring autophagy-dependent ferroptosis. Methods Cell Biol. 165, 163–176 (2021).
pubmed: 34311865
doi: 10.1016/bs.mcb.2020.10.012
Wang, F. et al. PALP: a rapid imaging technique for stratifying ferroptosis sensitivity in normal and tumor tissues in situ. Cell Chem. Biol. 29, 157–170 e156 (2022).
pubmed: 34813762
doi: 10.1016/j.chembiol.2021.11.001
Wang, F., Naowarojna, N. & Zou, Y. Stratifying ferroptosis sensitivity in cells and mouse tissues by photochemical activation of lipid peroxidation and fluorescent imaging. Star. Protoc. 3, 101189 (2022).
pubmed: 35345595
pmcid: 8956817
doi: 10.1016/j.xpro.2022.101189
Drummen, G. P., van Liebergen, L. C., Op den Kamp, J. A. & Post, J. A. C11-BODIPY(581/591), an oxidation-sensitive fluorescent lipid peroxidation probe: (micro)spectroscopic characterization and validation of methodology. Free. Radic. Biol. Med. 33, 473–490 (2002).
pubmed: 12160930
doi: 10.1016/S0891-5849(02)00848-1
Hirayama, T., Okuda, K. & Nagasawa, H. A highly selective turn-on fluorescent probe for iron(II) to visualize labile iron in living cells. Chem. Sci. 4, 1250–1256, (2013).
doi: 10.1039/c2sc21649c
Kapralov, A. A. et al. Redox lipid reprogramming commands susceptibility of macrophages and microglia to ferroptotic death. Nat. Chem. Biol. 16, 278–290 (2020).
pubmed: 32080625
pmcid: 7233108
doi: 10.1038/s41589-019-0462-8
Weigand, I. et al. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 11, 192 (2020).
pubmed: 32184394
pmcid: 7078189
doi: 10.1038/s41419-020-2385-4
Zhao, N. et al. Ferronostics: measuring tumoral ferrous iron with PET to predict sensitivity to iron-targeted cancer therapies. J. Nucl. Med. 62, 949–955 (2021).
pubmed: 33246980
doi: 10.2967/jnumed.120.252460
Phyo, A. P. et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect. Dis. 16, 61–69 (2016).
pubmed: 26448141
pmcid: 4700386
doi: 10.1016/S1473-3099(15)00320-5
Feng, H. et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 30, 3411–3423 e3417 (2020).
pubmed: 32160546
pmcid: 7172030
doi: 10.1016/j.celrep.2020.02.049
Shibata, Y., Yasui, H., Higashikawa, K. & Kuge, Y. Transferrin-based radiolabeled probe predicts the sensitivity of human renal cancer cell lines to ferroptosis inducer erastin. Biochem. Biophys. Rep. 26, 100957 (2021).
pubmed: 33681481
pmcid: 7910409
McCormick, P. N. et al. Assessment of tumor redox status through (S)-4-(3-[
pubmed: 30401715
doi: 10.1158/0008-5472.CAN-18-2634
Hoehne, A. et al. [18F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis. J. Neuroinflammation 15, 55 (2018).
pubmed: 29471880
pmcid: 5822551
doi: 10.1186/s12974-018-1080-1
Park, S. Y. et al. Clinical evaluation of (4S)-4-(3-[
pubmed: 32694158
doi: 10.1158/1078-0432.CCR-20-0644
Park, S. Y. et al. Initial evaluation of (4S)-4-(3-[
pubmed: 32857284
pmcid: 7455665
doi: 10.1186/s13550-020-00678-2
Zeng, F. et al. Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac/kidney injuries. Sci. Adv. 9, eadd8539 (2023).
pubmed: 36888714
pmcid: 9995079
doi: 10.1126/sciadv.add8539
Zhang, C. et al. Fe-based theranostic agents respond to the tumor microenvironment for MRI-guided ferroptosis-/apoptosis-inducing anticancer therapy. ACS Biomater. Sci. Eng. 8, 2610–2623 (2022).
pubmed: 35652940
doi: 10.1021/acsbiomaterials.1c01626
Zhu, L. et al. Efficient magnetic nanocatalyst-induced chemo- and ferroptosis synergistic cancer therapy in combination with T
pubmed: 35005898
doi: 10.1021/acsami.1c17507
Chen, Q. et al. Iron-based nanoparticles for MR imaging-guided ferroptosis in combination with photodynamic therapy to enhance cancer treatment. Nanoscale 13, 4855–4870 (2021).
pubmed: 33624647
doi: 10.1039/D0NR08757B
Zheng, J. & Conrad, M. The metabolic underpinnings of ferroptosis. Cell Metab. 32, 920–937 (2020).
pubmed: 33217331
doi: 10.1016/j.cmet.2020.10.011
Bayir, H. et al. Achieving life through death: redox biology of lipid peroxidation in ferroptosis. Cell Chem. Biol. 27, 387–408 (2020).
pubmed: 32275865
pmcid: 7218794
doi: 10.1016/j.chembiol.2020.03.014
Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405–414 (2019).
pubmed: 31101865
doi: 10.1038/s41568-019-0149-1
Gu, Y. et al. Targeting ferroptosis: paving new roads for drug design and discovery. Eur. J. Med. Chem. 247, 115015 (2023).
pubmed: 36543035
doi: 10.1016/j.ejmech.2022.115015
Wang, D. et al. Regulatory pathways and drugs associated with ferroptosis in tumors. Cell Death Dis. 13, 544 (2022).
pubmed: 35688814
pmcid: 9187756
doi: 10.1038/s41419-022-04927-1
Jin, J. et al. Machine learning classifies ferroptosis and apoptosis cell death modalities with TfR1 immunostaining. ACS Chem. Biol. 17, 654–660 (2022).
pubmed: 35230809
pmcid: 8938922
doi: 10.1021/acschembio.1c00953
Shibata, Y., Yasui, H., Higashikawa, K., Miyamoto, N. & Kuge, Y. Erastin, a ferroptosis-inducing agent, sensitized cancer cells to X-ray irradiation via glutathione starvation in vitro and in vivo. PLoS ONE 14, e0225931 (2019).
pubmed: 31800616
pmcid: 6892486
doi: 10.1371/journal.pone.0225931
Liu, W. et al. Ferroptosis inducer improves the efficacy of oncolytic virus-mediated cancer immunotherapy. Biomedicines 10, 1425 (2022).
pubmed: 35740445
pmcid: 9219720
doi: 10.3390/biomedicines10061425
Lu, Z. et al. Combined anti-cancer effects of platycodin D and sorafenib on androgen-independent and PTEN-deficient prostate cancer. Front. Oncol. 11, 648985 (2021).
pubmed: 34026624
pmcid: 8138035
doi: 10.3389/fonc.2021.648985
Oh, S. J., Erb, H. H., Hobisch, A., Santer, F. R. & Culig, Z. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr. Relat. Cancer 19, 305–319 (2012).
pubmed: 22383427
pmcid: 3353237
doi: 10.1530/ERC-11-0298
Roh, J. L., Kim, E. H., Jang, H. & Shin, D. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition. Free. Radic. Biol. Med. 104, 1–9 (2017).
pubmed: 28057599
doi: 10.1016/j.freeradbiomed.2017.01.002
Cobler, L., Zhang, H., Suri, P., Park, C. & Timmerman, L. A. xCT inhibition sensitizes tumors to gamma-radiation via glutathione reduction. Oncotarget 9, 32280–32297 (2018).
pubmed: 30190786
pmcid: 6122354
doi: 10.18632/oncotarget.25794
Nagane, M. et al. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma. PLoS ONE 13, e0195151 (2018).
pubmed: 29649284
pmcid: 5896924
doi: 10.1371/journal.pone.0195151
Shamaa, M. M. Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins. FEBS Open. Bio 11, 588–597 (2021).
pubmed: 33289342
pmcid: 7931239
doi: 10.1002/2211-5463.13052
Chen, C. et al. Flubendazole plays an important anti-tumor role in different types of cancers. Int. J. Mol. Sci. 23, 519 (2022).
pubmed: 35008943
pmcid: 8745596
doi: 10.3390/ijms23010519
Zhou, X. et al. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol. Res. 164, 105305 (2021).
pubmed: 33197601
doi: 10.1016/j.phrs.2020.105305
Li, M. et al. RSL3 enhances the antitumor effect of cisplatin on prostate cancer cells via causing glycolysis dysfunction. Biochem. Pharmacol. 192, 114741 (2021).
pubmed: 34428443
doi: 10.1016/j.bcp.2021.114741
Wang, J. et al. Inhibition of phosphoglycerate dehydrogenase induces ferroptosis and overcomes enzalutamide resistance in castration-resistant prostate cancer cells. Drug Resist. Updat. 70, 100985 (2023).
pubmed: 37423117
doi: 10.1016/j.drup.2023.100985
Zhao, R. et al. ATF6ɑ promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis. Prostate 82, 617–629 (2022).
pubmed: 35089606
pmcid: 9303695
doi: 10.1002/pros.24308
Wang, H. et al. Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells. Eur. J. Med. Chem. 254, 115343 (2023).
pubmed: 37087895
doi: 10.1016/j.ejmech.2023.115343
Eling, N., Reuter, L., Hazin, J., Hamacher-Brady, A. & Brady, N. R. Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience 2, 517–532 (2015).
pubmed: 26097885
pmcid: 4468338
doi: 10.18632/oncoscience.160
Luo, J. et al. Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo. Radiat. Oncol. 9, 84 (2014).
pubmed: 24666614
pmcid: 3987175
doi: 10.1186/1748-717X-9-84
Yin, X. et al. Artesunate suppresses the proliferation and development of estrogen receptor-alpha-positive endometrial cancer in HAND2-dependent pathway. Front. Cell Dev. Biol. 8, 606969 (2020).
pubmed: 33511117
doi: 10.3389/fcell.2020.606969
Zhang, Z. Y. et al. [Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial]. Zhong Xi Yi Jie He Xue Bao 6, 134–138 (2008).
pubmed: 18241646
doi: 10.3736/jcim20080206
Sun, Y. et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells. Cell Death Dis. 12, 1028 (2021).
pubmed: 34716292
pmcid: 8556316
doi: 10.1038/s41419-021-04306-2
Khalil, R. et al. Withaferin A increases the effectiveness of immune checkpoint blocker for the treatment of non-small cell lung cancer. Cancers 15, 3089 (2023).
pubmed: 37370701
pmcid: 10295988
doi: 10.3390/cancers15123089
Kim, S. H. et al. RNA-seq reveals novel mechanistic targets of withaferin A in prostate cancer cells. Carcinogenesis 41, 778–789 (2020).
pubmed: 32002539
pmcid: 7351133
doi: 10.1093/carcin/bgaa009
Kyakulaga, A. H., Aqil, F., Munagala, R. & Gupta, R. C. Synergistic combinations of paclitaxel and withaferin A against human non-small cell lung cancer cells. Oncotarget 11, 1399–1416 (2020).
pubmed: 32362998
pmcid: 7185067
doi: 10.18632/oncotarget.27519
Nishikawa, Y. et al. Withaferin A induces cell death selectively in androgen-independent prostate cancer cells but not in normal fibroblast cells. PLoS ONE 10, e0134137 (2015).
pubmed: 26230090
pmcid: 4521694
doi: 10.1371/journal.pone.0134137
Yang, E. S., Choi, M. J., Kim, J. H., Choi, K. S. & Kwon, T. K. Combination of withaferin A and X-ray irradiation enhances apoptosis in U937 cells. Toxicol. Vitr. 25, 1803–1810 (2011).
doi: 10.1016/j.tiv.2011.09.016
Kristensen, G. B., Baekelandt, M., Vergote, I. B. & Trope, C. A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. Eur. J. Cancer 31A, 1778–1780 (1995).
pubmed: 8541099
doi: 10.1016/0959-8049(95)00274-M
Malik, I. A. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. Jpn. J. Clin. Oncol. 31, 69–73 (2001).
pubmed: 11302345
doi: 10.1093/jjco/hye012
Woo, J. H. et al. Elucidating compound mechanism of action by network perturbation analysis. Cell 162, 441–451 (2015).
pubmed: 26186195
pmcid: 4506491
doi: 10.1016/j.cell.2015.05.056
Wang, L., Chen, X. & Yan, C. Ferroptosis: an emerging therapeutic opportunity for cancer. Genes. Dis. 9, 334–346 (2022).
pubmed: 35224150
doi: 10.1016/j.gendis.2020.09.005
Qin, Z. et al. Design and synthesis of isothiocyanate-containing hybrid androgen receptor (AR) antagonist to downregulate AR and induce ferroptosis in GSH-deficient prostate cancer cells. Chem. Biol. Drug. Des. 97, 1059–1078 (2021).
pubmed: 33470049
pmcid: 8168342
doi: 10.1111/cbdd.13826
Li, Q. et al. The effects of buthionine sulfoximine on the proliferation and apoptosis of biliary tract cancer cells induced by cisplatin and gemcitabine. Oncol. Lett. 11, 474–480 (2016).
pubmed: 26870236
doi: 10.3892/ol.2015.3879
Bump, E. A. & Brown, J. M. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol. Ther. 47, 117–136 (1990).
pubmed: 2195553
doi: 10.1016/0163-7258(90)90048-7
Guo, J. et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res. Treat. 50, 445–460 (2018).
pubmed: 28494534
doi: 10.4143/crt.2016.572
Efferth, T. Cancer combination therapies with artemisinin-type drugs. Biochem. Pharmacol. 139, 56–70 (2017).
pubmed: 28366726
doi: 10.1016/j.bcp.2017.03.019
Sundar, S. N., Marconett, C. N., Doan, V. B., Willoughby, J. A. Sr & Firestone, G. L. Artemisinin selectively decreases functional levels of estrogen receptor-ɑ and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 29, 2252–2258 (2008).
pubmed: 18784357
pmcid: 2639250
doi: 10.1093/carcin/bgn214
Wang, T. et al. Combination treatment with artemisinin and oxaliplatin inhibits tumorigenesis in esophageal cancer EC109 cell through Wnt/β-catenin signaling pathway. Thorac. Cancer 11, 2316–2324 (2020).
pubmed: 32657048
pmcid: 7396387
doi: 10.1111/1759-7714.13570
Willoughby, J. A. Sr. et al. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J. Biol. Chem. 284, 2203–2213 (2009).
pubmed: 19017637
pmcid: 2629082
doi: 10.1074/jbc.M804491200
Dai, X. et al. Dihydroartemisinin: a potential natural anticancer drug. Int. J. Biol. Sci. 17, 603–622 (2021).
pubmed: 33613116
pmcid: 7893584
doi: 10.7150/ijbs.50364
Han, W. et al. Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy. Biomaterials 280, 121315 (2022).
pubmed: 34920370
doi: 10.1016/j.biomaterials.2021.121315
Li, Q. et al. Dihydroartemisinin as a sensitizing agent in cancer therapies. Onco Targets Ther. 14, 2563–2573 (2021).
pubmed: 33880035
pmcid: 8053502
doi: 10.2147/OTT.S297785
Lin, R. et al. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells. Cancer Lett. 381, 165–175 (2016).
pubmed: 27477901
doi: 10.1016/j.canlet.2016.07.033
Abrams, R. P., Carroll, W. L. & Woerpel, K. A. Five-membered ring peroxide selectively initiates ferroptosis in cancer cells. ACS Chem. Biol. 11, 1305–1312 (2016).
pubmed: 26797166
pmcid: 5507670
doi: 10.1021/acschembio.5b00900
Gaschler, M. M. et al. FINO
pubmed: 29610484
pmcid: 5899674
doi: 10.1038/s41589-018-0031-6
Saha, A. et al. Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition. J. Exp. Clin. Cancer Res. 42, 119 (2023).
pubmed: 37170264
pmcid: 10173527
doi: 10.1186/s13046-023-02677-2
Badgley, M. A. et al. Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85–89 (2020).
pubmed: 32241947
pmcid: 7681911
doi: 10.1126/science.aaw9872